Evidence map›Paper›PMID 33953401›Full record

ArticleNature2021

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.

Gabriel K Griffin, Jingyi Wu, Arvin Iracheta-Vellve, James C Patti, Jeffrey Hsu, Thomas Davis, Deborah Dele-Oni, Peter P Du, Aya G Halawi, Jeffrey J Ishizuka and 19 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 252 papers.

0numbers the graph read from it
0cells of the map it votes in
252citing papers in PubMed
20.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

252 citing papers in PubMed, 341 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

192 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors at 2 institutions in 1 country.

Gabriel K Griffin *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Jingyi Wu *Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Arvin Iracheta-Vellve *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6635-3904
James C PattiBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1733-6702
Jeffrey HsuBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6065-4653
Thomas DavisBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Deborah Dele-OniBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Peter P DuBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2652-0541
Aya G HalawiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jeffrey J IshizukaDepartment of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Sarah Y KimBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Susan KlaegerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0074-5163
Nelson H KnudsenBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0384-1097
Brian C MillerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5931-4184
Tung H NguyenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kira E OlanderBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Malvina PapanastasiouBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3378-6612
Suzanna RachimiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Emily J RobitschekBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Emily M SchneiderBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5778-9119
Mitchell D YearyBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Margaret D ZimmerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jacob D JaffeBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9845-1210
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
W Nicholas HainingBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Kathleen B YatesBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Robert T MangusoBroad Institute of MIT and Harvard, Cambridge, MA, USA. rmanguso@mgh.harvard.edu.ORCID http://orcid.org/0000-0003-1336-413X
Bradley E BernsteinBroad Institute of MIT and Harvard, Cambridge, MA, USA. bernstein.bradley@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-5726-6278
Broad Institute · USHarvard University · US

Funding

MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0M
Center of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4M
Epigenetic plasticity in tumor initiation and evolutionDP1CA216873 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BERNSTEIN, BRADLEY EVAN · 2016 to 2020
$5.9M
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to ImmunotherapyK08CA245112 · NCI · YALE UNIVERSITY · PI ISHIZUKA, JEFFREY J. · 2020 to 2024
$1.3M
Targeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer MutationsK08CA248960 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MILLER, BRIAN C · 2020 to 2024
$1.2M
NCI NIH HHS DP1 CA216873NCI NIH HHS K08 CA245112NCI NIH HHS U01 CA214125NCI NIH HHS U24 CA210986
6 · The paper itself

Abstract

Epigenetic dysregulation is a defining feature of tumorigenesis that is implicated in immune escape

Indexed as

Gene SilencingAnimalsAntigens, ViralChromatinCRISPR-Cas SystemsDisease Models, AnimalDNA Transposable ElementsFemaleHistocompatibility Antigens Class IHistone-Lysine N-MethyltransferaseHumansMiceNeoplasmsProgrammed Cell Death 1 ReceptorT-Lymphocytes, CytotoxicAntigens, ViralChromatinDNA Transposable ElementsHistocompatibility Antigens Class IHistone-Lysine N-MethyltransferaseProgrammed Cell Death 1 ReceptorSETDB1 protein, human

Identifiers

PMID33953401
PMCPMC9166167
OpenAlexW3158155618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.